Advertisement
Screener

INTELLIGENT BIO SOLUTIONS INC. (INBS) Graph

INBS Revenue Flow

Filed revenue amounts for 2025-07-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $1.15M*; Cost of revenue $609.22K*; Research and development (m); Selling, general and administrative $2.99M*.
  • 2026-03-31: Revenue $1.06M; Cost of revenue $525.42K; Research and development (m); Selling, general and administrative $2.46M.
  • 2025-12-31: Revenue $896.77K; Cost of revenue $437.04K; Research and development (m); Selling, general and administrative $2.34M.
  • 2025-09-30: Revenue $1.11M; Cost of revenue $593.51K; Research and development (m); Selling, general and administrative (m).

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

INBS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Other SalesAccessories$827.35KSales Of GoodsCartidges$2.49MSales Of Goods Readers$902.26KRevenue$4.22MCost of revenue$2.17MGross profit$2.05MOperating expenses$15.34MOperating income-$12.61MOther income, net$139.41KSelling, general& administrative$10.50M

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

INBS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Americas$8.75KAsia Pacific$12.47KOther Country$40.20KGB$4.15MRevenue$4.22MCost of revenue$2.17MGross profit$2.05MOperating expenses$15.34MOperating income-$12.61MOther income, net$139.41KSelling, general& administrative$10.50M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$1.15M*$609.22K*(m)$2.99M*$4.75M*-$3.91M*
2026-03-31$1.06M$525.42K(m)$2.46M$3.65M-$2.86M
2025-12-31$896.77K$437.04K(m)$2.34M$3.17M-$2.68M
2025-09-30$1.11M$593.51K(m)(m)$3.71M-$2.98M
2025-03-31$728.87K$387.50K(m)$2.41M$3.07M-$2.54M
2024-12-31$607.49K$384.38K(m)$1.81M$2.62M-$2.25M
2024-09-30$872.29K$525.49K(m)(m)$3.20M-$2.69M
2024-03-31(m)$645.31K(m)(m)$3.22M-$2.98M
2023-12-31(m)$564.82K(m)$1.71M$2.34M-$1.97M
2023-09-30(m)$563.76K(m)(m)$2.87M-$2.43M
2023-03-31$457.06K$424.01K(m)(m)$6.69M-$6.34M
2022-12-31$356.68K$112.64K(m)$2.25M$2.64M-$420.60K
2022-09-30$311.32K(m)(m)(m)$1.53M-$1.21M
2022-06-30$66.86K*(m)(m)(m)(m)(m)
2022-03-31$192.50K(m)(m)(m)$1.54M-$1.34M
2021-12-31$177.79K(m)(m)(m)$3.64M-$3.46M
2021-09-30(m)(m)(m)(m)$1.44M-$1.43M
2021-03-31$34.29K(m)(m)(m)$3.17M-$3.13M
2020-12-31$283.04K(m)$341.82K(m)$1.20M-$1.98M
2020-09-30$55.43K(m)(m)(m)$718.42K-$1.07M
2020-06-30(m)(m)(m)(m)(m)-$1.84M
2020-03-31-$1.53K(m)(m)(m)$27.29K-$112.59K
2019-12-31-$798.00(m)$494.67K(m)$1.70M-$1.84M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2025-12-31$2.01M$1.03M(m)$5.00M$6.88M-$5.66M
2024-12-31$1.48M$909.87K(m)$3.76M$5.82M-$4.94M
2023-12-31(m)$1.13M(m)$4.16M$5.21M-$4.39M
2022-12-31$356.68K$112.64K(m)$3.70M$4.17M-$1.63M
2021-12-31$177.79K(m)(m)(m)$5.08M-$4.89M
2020-12-31$338.46K(m)$372.76K(m)$1.92M-$3.06M
2020-06-30(m)(m)(m)(m)(m)-$2.59M
2019-12-31$121.28K(m)$599.85K(m)$2.44M-$2.59M

Revenue and expense 9 month

Period endRevenueCost of revenueSelling, general and administrativeOperating expensesNet income
2026-03-31$3.07M$1.56M$7.51M$10.58M-$8.52M
2025-03-31$2.21M$1.30M$6.20M$8.92M-$7.48M
2024-03-31(m)$1.77M(m)$8.43M-$7.37M
2023-03-31$813.74K$536.64K(m)$10.87M-$7.97M
2022-03-31$370.29K(m)(m)$6.62M-$6.23M
2021-03-31$372.75K(m)(m)$5.09M-$6.18M
2020-03-31$119.74K(m)(m)$2.47M-$2.71M

Revenue and expense 12 month

Period endRevenueCost of revenueSelling, general and administrativeOperating expensesNet income
2026-06-30$4.22M$2.17M$10.50M$15.34M-$12.43M
2025-06-30$3.05M$1.81M$8.92M$12.74M-$10.57M
2024-06-30$3.11M$1.69M(m)$12.13M-$10.16M
2023-06-30$1.26M$930.20K(m)$13.66M-$10.63M
2022-06-30$437.15K(m)(m)$8.77M-$8.31M
2021-06-30$1.98M(m)(m)$7.55M-$7.04M
2020-06-30$188.74K(m)(m)$3.05M-$3.16M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sonoma Pharmaceuticals, Inc. (SNOA)United States$0.006B-2.59
AETHLON MEDICAL INC (AEMD)United States$0.005B
enVVeno Medical Corp (NVNO)United States$0.006B-0.48
Bluejay Diagnostics, Inc. (BJDX)United States$0.004B
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Autonomix Medical, Inc. (AMIX)United States$0.004B
Co-Diagnostics, Inc. (CODX)United States$0.007B-0.32
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
Vivos Therapeutics, Inc. (VVOS)United States$0.003B-0.26